Evidence map›Paper›PMID 33922657›Full record

ArticleInternational journal of molecular sciences2021

Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.

Wei-Che Tseng, Chi-Yuan Chen, Ching-Yuh Chern, Chu-An Wang, Wen-Chih Lee, Ying-Chih Chi, Shu-Fang Cheng, Yi-Tsen Kuo, Ya-Chen Chiu, Shih-Ting Tseng and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Protective Effect of Curcuma Extract in anOxidative medicine and cellular longevity · 2022
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Wei-Che TsengGraduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Chi-Yuan ChenTissue Bank, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Ching-Yuh ChernDepartment of Applied Chemistry, National Chiayi University, Chiayi 600, Taiwan.
Chu-An WangDepartment of Physiology, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
Wen-Chih LeeTranslational Research Program in Pediatric Orthopedics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0001-6436-731X
Ying-Chih ChiCryo-EM Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA.
Shu-Fang ChengGraduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Yi-Tsen KuoGraduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Ya-Chen ChiuGraduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Shih-Ting TsengGraduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Pei-Ya LinGraduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Shou-Jhen LiouGraduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Yi-Chen LiDepartment of Applied Chemistry, National Chiayi University, Chiayi 600, Taiwan.
Chin-Chuan ChenGraduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Chang Gung University · TWChang Gung University of Science and Technology · TWNational Chiayi University · TWChildren's Hospital of Philadelphia · USColumbia University · USNational Cheng Kung University · TW

Funding

Chang Gung Memorial Hospital CMRPD1J0141-3Ministry of Science and Technology of Taiwan 109-2628-B-182-026
6 · The paper itself

Abstract

BRCA mutation, one of the most common types of mutations in breast and ovarian cancer, has been suggested to be synthetically lethal with depletion of RAD52. Pharmacologically inhibiting RAD52 specifically eradicates BRCA-deficient cancer cells. In this study, we demonstrated that curcumin, a plant polyphenol, sensitizes BRCA2-deficient cells to CPT-11 by impairing RAD52 recombinase in MCF7 cells. More specifically, in MCF7-siBRCA2 cells, curcumin reduced homologous recombination, resulting in tumor growth suppression. Furthermore, a BRCA2-deficient cell line, Capan1, became resistant to CPT-11 when BRCA2 was reintroduced. In vivo, xenograft model studies showed that curcumin combined with CPT-11 reduced the growth of BRCA2-knockout MCF7 tumors but not MCF7 tumors. In conclusion, our data indicate that curcumin, which has RAD52 inhibitor activity, is a promising candidate for sensitizing BRCA2-deficient cells to DNA damage-based cancer therapies.

Indexed as

DNA DamageHomologous RecombinationAnimalsAntineoplastic AgentsApoptosisBRCA2 ProteinBreast NeoplasmsCell ProliferationCurcuminDNA RepairFemaleGene Expression Regulation, NeoplasticHumansIrinotecanMiceMice, NudeAntineoplastic AgentsBRCA2 ProteinBRCA2 protein, humanCurcuminIrinotecanRad52 DNA Repair and Recombination ProteinRAD52 protein, humanTopoisomerase I InhibitorsBRCA-deficientcurcuminDNA repairRAD52 inhibitorsynthetic lethal

Identifiers

PMID33922657
PMCPMC8122931
OpenAlexW3158153434

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.